For Which Infections is Ceftazidime-Avibactam Approved?
FEB 13, 2017 | CONTAGION EDITORIAL STAFF
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.
Interview Transcript (slightly modified for readability)
“[Ceftazidime-avibactam] is currently only FDA-approved for intra-abdominal infections and urinary tract infections; however, it seems like a lot of people are using it for a lot of other infections, more severe infections [like] bacteremias [and] pneumonias. I’ve seen posters at these infectious disease conferences [that imply that] people are using it in other infections, and I’ve personally used [ceftazidime-avibactam] in other infections.
So [this combination is] only approved for two infections in the US, but in Europe it’s actually approved for pneumonia, as of, I believe, summer .”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512